SUMMARY
ADAMTS13 is a plasma metalloproteinase that cleaves von Willebrand Factor to smaller less thrombogenic forms. Deficiency of ADAMTS13 activity in plasma leads to thrombotic thrombocytopenic purpura. ADAMTS13 contains eight thrombospondin type 1 repeats (TSR), seven of which contain a consensus sequence for the direct addition of fucose to the hydroxyl group of serine or threonine. Mass spectral analysis of tryptic peptides derived from human ADAMTS13 indicate that at least six of the TSRs are modified with an O-fucose disaccharide. Analysis of [ 3 H]fucose metabolically incorporated into ADAMTS13 demonstrated that the disaccharide has the structure Glucose-ß1,3-Fucose. Mutation of the modified serine to alanine in TSRs 2, 5, 7, and 8 reduced the secretion of ADAMTS13. Mutation of more than one site dramatically reduced secretion regardless of the sites mutated. When the expression of protein O-fucosyltransferase 2 (POFUT2), the enzyme that transfers fucose to serines in TSRs, was reduced using siRNA, the secretion of ADAMTS13 decreased. A similar outcome was observed when ADAMTS13 was expressed in a cell line unable to synthesize the donor for fucose addition, GDP-fucose. While overexpression of POFUT2 did not affect the secretion of wild-type ADAMTS13, it did increase the secretion of the ADAMTS13 TSR1,2 double mutant but not that of ADAMTS13 TSR1-8 mutant. Together these findings indicate that O-fucosylation is functionally significant for secretion of ADAMTS13.
INTRODUCTION
ADAMTS13 is a plasma metalloprotease that cleaves von Willebrand Factor to smaller, less thrombogenic fragments. ADAMTS13 is a member of the ADAMTS family of metalloproteases that are characterized by a conserved domain structure. These include a metalloprotease domain, a disintegrin domain, a thrombospondin type 1 repeat (TSR), cysteinerich domain, a spacer domain and conclude with a variable number of additional TSRs (1) . ADAMTS13 uniquely contains seven additional TSRs and two CUB1 domains at its carboxyl end (2-4) ( Figure 1A ).
TSRs contain approximately 60 amino acids with conserved tryptophans and cysteines. They were first described in thrombospondin type 1 and are homologous to the properdin repeat found in many components of the complement system. Thrombospondin type 1 is a protein that is thought to play a role in angiogenesis, cell adhesion and motility (5, 6) . Many interactions of thrombospondin-1 are thought to be mediated through amino acids within the TSRs (7) . For example, binding of thrombospondin-1 to the endothelial cell protein, CD36, can be inhibited by the peptide CSVTCG which is found in the TSRs of thrombospondin-1 (8) . The three TSRs of thrombospondin-1 have been shown to contain a fucose directly linked to a serine or threonine within a putative consensus sequence of C 1 XX(S/T)C 2 G (where C 1 and C 2 are the first and second conserved cysteines in the TSR (9)), which is the putative CD36 binding region. The fucose on the TSRs was further modified with a glucose in β1-3 linkage to form a disaccharide (9, 10) . Subsequent analysis of O-fucosylation on TSRs from properdin and F-spondin resulted in a revised consensus sequence: WX 5 C 1 X 2-
(S/T)C 2 X 2 G (11).
O-fucosylation of proteins has also been described on epidermal growth factor (EGF)-like repeats of many different proteins, including urinary-type plasminogen activator, coagulation factors VII, IX, and XII, and the developmental protein, Notch (12, 13) . The O-fucose in the EGF-like repeats of factor IX and Notch can be further modified with an N-acetylglucosamine, galactose, and sialic acid (13, 14) . Fucosylation and the further elongation of the saccharide is critical for the activity of Notch (15) (16) (17) (18) (19) . Fucosylation of urinary-type plasminogen activator is also important for the activation of its receptor (20) .
The enzyme responsible for the addition of fucose to serines or threonines of EGF-like repeats was identified as protein Ofucosyltransferase 1 (POFUT1) (21) . While other known fucosyltransferases are Golgi resident proteins, POFUT1 is a soluble protein that contains a KDEL-like sequence and localizes to the endoplasmic reticulum (ER) (22, 23) . POFUT1 only fucosylates properly folded EGF-like repeats, suggesting it may play some role in quality control (24) . Studies with Notch have shown that POFUT1 is required for localization of Notch to the plasma membrane (22) . Interestingly, an enzymatically inactive mutant of the Drosophila homologue, OFUT1, was able to restore plasma membrane localization of Notch in cells that lacked OFUT1 (22) . Along with the ER localization, this result suggests that POFUT1 may have a chaperone role in addition to its fucosyltransferase activity.
POFUT1 is unable to fucosylate TSR repeats, a process mediated by a second protein fucosyltransferase, POFUT2 (10, 25) . POFUT2 fucosylates TSRs of thrombospondin-1 but not EGF-like repeats. POFUT2 is also localized to the ER but does not contain a KDEL-like sequence (25, 26) . Interestingly, POFUT2 also only modifies properly folded TSRs, suggesting it too may play some role in quality control (10) . To better understand the role of POFUT2 and fucosylation of TSRs, we have studied the role of fucosylation in the secretion and activity of ADAMTS13, which contains seven potential fucosylation sites in its eight TSRs ( Figure 1B ). This work examines the functional significance of O-fucosylation in TSRs.
EXPERIMENTAL PROCEDURES
PlasmidspcDNA4/TO (Invitrogen) and ADAMTS13 in pcDNA 3.1/V5 His (27) were digested with NdeI and HindIII. The 500 nucleotide fragment from pcDNA4/TO containing the tetracycline operon was ligated into the 5000 nucleotide fragment of ADAMTS13 in pcDNA3.1/V5 His to generate a construct with tetracycline-inducible expression and a V5 epitope tag (ADAMTS13 in TOV5.) A silent EcoRI site was introduced into the ADAMTS13 coding sequence by changing a G to an A at nucleotide 2918 and a C to a T at nucleotide 2921 by site-directed mutagenesis using QuikChange (Stratagene) and the primers listed in Table 1 (EcoRI ADAMTS13) . After digestion with HindIII and EcoRI, the 2918 nucleotide fragment was ligated into pBlueScript SK (Stratagene) also digested with HindIII and EcoRI to generate 5' ADAMTS13 in pBlueScript. Similarly, EcoRI ADAMTS13 was digested with EcoRI and NotI and the 1359 nucleotide fragment was ligated with EcoRI and NotI digested pBluescript SK to generate 3' ADAMTS13 in pBluescript. The cDNA encoding POFUT2 was amplified from a human placenta cDNA library (Clontech) with an amino-or carboxyl-Flag epitope tag using the primers listed in Table 1 and ligated into pcDNA3.1V5/His TA TOPO. To generate the pSignal Sequence vector, phosphorylated oligonucleotides with digested HindIII sites and the sequence encoding the Ig κ-chain leader sequence were ligated with HindIII digested, alkaline phosphatase-treated TOV5. After digestion of amino-Flag POFUT2 in pcDNA3.1 V5/His with Kpn I and XbaI, the ∼1300 nucleotide fragment was ligated with KpnI/XbaI digested pSignal Sequence. The resulting construct encodes amino acids METDTLLLWVLLLWVPGSTGDASLVPRSS DPLVQCGGIALDYKDDDDK before the POFUT2 sequence of GQFWPG. POFUT2 E395A/E396A was generated using site-directed mutagenesis as previously described and the primers in Table 1 . pSVH-D'D3pro-c-Myc, which encodes the signal sequence, and D'D3 domains of von Willebrand Factor, was a gift of Dr. Angie Purvis (28) .
Cell linesParental HEK293 TREx cells (Invitrogen) were grown in Dulbecco's modified Eagle's media with 10% tetracycline-free fetal bovine serum (Clontech) and 5µg/ml blasticidin. Lec13-CHO cell line was generated by Dr. Pamela Stanley (29) and were grown in α-Minimal Essential Media containing 10% fetal bovine serum in the presence or absence of 1 mM L-fucose (Sigma). the presence of 1 µl/ml Protease Inhibtor Cocktail (Sigma) and 1 mM phenylmethylsulfonyl fluoride (PMSF). The cells were washed with phosphate-buffered saline and lysed in 1 ml radio-immune precipitation assay buffer (RIPA) buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) on ice for greater than 10 minutes. Insoluble cellular material was pelleted by centrifugation at 14,000 X g for ten minutes. Anti-V5 antibody and Protein GSepharose were added to equivalent fractions of the cell lysate and medium for immunoprecipitation. The immunoprecipitates were prepared for Peptide: N-glycanase F digestion following the manufacturer's directions (New England Biolabs). Briefly, the immunoprecipitates were incubated in denaturing buffer at 100 o C for five minutes and then, sodium phosphate pH 7.5, Nonidet P-40 were added. To one-half of each immunoprecipitate, Peptide: N-glycanase F was added. The control reaction was incubated in the absence of N-glycanase F. After incubation at three hours at 37 o C, the samples were subjected to SDS-PAGE. The gel was incubated in 25% isopropanol, 10% acetic acid, Amplify (Amersham), dried under vacuum and exposed to film at -70 o C with an intensifying screen.
Release of O-fucose glycans by alkali-induced ß-elimination and chromatographic
analysis-ADAMTS13 radiolabeled with [ 3 H]fucose (from both media and cell lysates) was treated with peptide: N-glycanse F as described above, and the protein was separated from released N-glycans by Sephadex G-50 gel filtration chromatography as described (31) . The O-glycans were then released by alkaliinduced ß-elimination, and the released glycans analyzed chromatographically (gel filtration on a Superdex peptide column, high pH anion exchange chromatography on an MA-1 column) as described (32) . Figure 3 ). The mass of the unglycosylated peptide was matched to the masses of the predicted tryptic peptides from human ADAMTS13 that contain a predicted O-fucose modification site (C 1 XX(S/T)C 2 XXG). Since each of these peptides has a unique mass (see Table 3 ), there were no ambiguities in assigning the spectra. The presence of b-and/or y-ions (34) in the MS/MS data from fragmentation of the unglycoslated peptide confirmed the assignments. Due to the lability of the glycosidic linkage, assignment of the modified serine or threonine could not be reliably done. Thus, the assignment of the modified residue was based on the consensus sequence. Once glycopeptides were identified, additional searches were performed for unglycosylated peptides, or glycopeptides modified with fucose only.
Generation of O-fucosylation site mutations in ADAMTS13
Serines at positions 399, 698, 757, 907, 965 were individually changed to alanine by site-directed mutagenesis of the HindIII/EcoRI ADAMTS13 fragment in pBluescript using QuikChange (Stratagene) according to the manufacturer's directions and the primers listed in Table 1 . To generate mutations of serines 1027 and 1087, the EcoRI/XbaI fragment of ADAMTS13 in pBluescript were used in site-directed mutagenesis reactions. The HindIII/EcoRI or EcoRI/XbaI fragments were re-ligated into ADAMTS13 in TOV5. Generation of double mutations was done by site-directed mutation of serine 399 to alanine in the cDNA encoding serine 698 to alanine. Similar double mutations were made with serines 907 and 965, and 1027 and 1087. The coding region of ADAMTS13 was sequenced to verify the serine to alanine codon change and the absence of other mutations.
Expression of wild-type and mutant proteins12 µg wild-type or mutant ADAMTS13 cDNA was transiently transfected into 100 mm dishes of HEK293 TREx cells (Invitrogen) that were approximately 75% confluent using 36 µl Lipofectamine and 24 µl Plus reagent (Invitrogen) according to the manufacturer's directions in 4 mls of Opti-Mem (Invitrogen). After transfection, the medium was changed to 5 mls Opti-Mem plus 1 µg/ml tetracycline and collected after three days. The cells were washed with phosphate-buffered saline and collected by scraping. The cells were lysed in RIPA buffer as described above. Equivalent fractions of the media and cell lysate were subjected to SDS-PAGE and transferred to Immobilon P (Millipore) by blotting. The blots were incubated with a 1:5000 dilution of peroxidase-conjugated anti-V5 epitope antibody in casein block solution and chemiluminescence was detected with SuperSignal West Pico (Pierce). The percent secretion was calculated after measuring the intensity of the chemiluminescent signal using a Kodak Image Station 440CF. The reported results are the mean of at least three experiments. Statistical significance was analyzed using the Student's ttest in comparison to the percent of wild-type ADAMTS13 secreted. Results with mutants with a p-value of >0.05 were considered not significantly different from those with wild-type ADAMTS13. Statistical calculations were done using software http://www.graphpad.com/quickcalcs/.
SiRNA of POFUT2RNA oligonucleotides for RNA silencing were created based on the criteria of Ui-Tei et al. with modifications (35) . The RNA primers complementary to nucleotides 1135-1153 of POFUT2 were GCACACGCCAGGUUUUUUUUU (sense) and UAAAAAACCUGGCGUGUGCGC (antisense). The control RNA primers directed against luciferase were CUUUACGCUGAGUACUUCGAdTdT (sense) and UCGAAGUACUCAGCGUAAGdTdT (antisense.) The primers were designed with an intentional sense mismatch at the 5-prime antisense base pair. 90 % confluent HEK293 TREx cells in 25cm 2 flasks were transfected using 8 µg of the annealed RNA primer pair, and 8 µg of ADAMTS13 or 8 µg of POFUT2 and 20 µl Lipofectamine 2000 (Invitrogen) according to the manufacturer's directions. 48 hours after transfection, 1 µg/µl tetracycline was added to de-repress transcription from the tetracycline operon. The medium and cells were collected and analyzed as described 72 hours posttransfection. Figure 2B , data for sample from cells is shown. Similar results were obtained for the samples from media). Very little O-fucose monosaccharide was seen. Analysis of the disaccharide by high pH anion exchange chromatography showed the disaccharide to be Glucose-ß1,3-Fucitol ( Figure 2C ), the same disaccharide found on TSRs from several other proteins (9-11). Since cellular ADAMTS13 is nearly exclusively present in the endoplasmic reticulum (ER) (27, 36) , the presence of the Glucose-ß1,3-Fucose disaccharide on cellular ADAMTS13 suggests both the fucose and glucose are added to TSRs in the ER. This is consistent with the reported localizations of both POFUT2 and the ß1,3-glucosyltransferase (25, 26, 37) . The increased intensity of the Figure 2A ). Interestingly, a small amount of oligosaccharide species was also seen in the analysis of O-fucose glycans (labeled "OS" in Figure 2B ). Acid hydrolysis of this material revealed the radiolabel to be mainly in the form of [ 3 H]fucitol (data not shown). Since fucitol is generated during the ß-elimination of O-fucose saccharides (but not with fucose on N-glycans), this result suggests the presence of an O-fucosecontaining oligosaccharide on ADAMTS13. Further studies will be required to define the structure of this species.
RESULTS

O-linked fucosylation of ADAMTS13
The presence of O-fucose disaccharide at the predicted sites ( Figure 1 ) was analyzed by tandem mass spectrometry. Tryptic peptides were generated from purified human ADAMTS13 and analyzed by LC-MS/MS as described in Experimental Procedures. Fragmentation of peptides modified with the disaccharide resulted in a characteristic pattern showing sequential losses of the glucose (Hex) and fucose (dHex) (Figure 3) . The major product ion in the MS/MS spectra corresponds to the unglycosylated peptide. The masses of the major product ions were matched to the predicted masses of tryptic peptides from human ADAMTS13 containing the O-fucose consensus sequence. Tryptic peptides containing six of the seven predicted O-fucosylation sites were identified by this method (within TSRs 2, 3, 5, 6, 7, and 8, see Table 2 and Supplemental Data). The peptide containing the O-fucosylation site from TSR1 was not identified in this analysis. Of the peptides observed, all were found modified with the disaccharide (consistent with the radiolabeling data shown in Figure 2B ), except for the peptide from TSR7, where both monosaccharide and disaccharide forms of Ofucose were observed (data not shown).
Mutation of fucosylation sites can impair secretion of ADAMTS13Since the function of
O-fucosylation on TSRs is unknown, the effect of O-linked fucosylation on the activity and secretion of ADAMTS13 was characterized. The fucosylated serines were individually mutated to alanines ( Figure 1B) . Figure 4 shows an example of expression of ADAMTS13 after individual mutation of the fucosylation sites. Unlike other ADAMTS family members, ADAMTS13 is secreted from the cell and is not associated with the plasma membrane or extracellular matrix (27) . Typically, about 58% of ADAMTS13 is secreted from the cell after 3 days of incubation. This can be seen in Figure  4A when the secreted ADAMTS13 in lane 8 is compared to the cellular ADAMTS13 in lane 7. TSR1 and TSR3 S to A had very little effect on the secretion of ADAMTS13 from HEK293 cells (compare lanes 1 and 2 and lanes 5 and 6 to lanes 7 and 8) but secretion of TSR2 S to A was dramatically decreased (compare lanes 3 and 4) . Secretion of TSR5, TSR6, TSR7, and TSR8 S to A were variably affected as seen in Figure 4B . The secretion of ADAMTS13 and the fucosylation site mutants from multiple experiments was quantified and the results are shown in Table 3 . Individual mutation of TSRs 2, 5, 7 and 8 had variable but significant changes in secretion from that of wild-type ADAMTS13. Mutation of fucosylation sites in TSR1, 3, 5, 6, 7, and 8 of ADAMTS13 had no effect on the cleavage of VWF (data not shown). Cleavage of VWF by TSR2 S to A was unable to be assessed because of the poor secretion of this mutant. TSR1-6 S to A and TSR1-8 S to A which contain an alanine instead of a serine in TSRs 1,2,3,5, and 6 and in TSRs1,2,3,5,6,7,8 respectively, were generated and expressed in HEK293 cells. Mutation of these multiple sites completely abolished secretion of ADAMTS13 as will be discussed below. Constructs were then made that contained two S to A mutations of TSRs ( Figure 5 ). Mutation of two sites greatly decreased secretion as can be seen with each of these constructs as compared to wildtype ADAMTS13 (compare lanes 4, 6, and 8 to lane 2). Mutation of TSR1+2 S to A essentially abolished secretion of ADAMTS13. Quantification of these results is reported in Table 3 . The double mutants were affected much more than the additive effect of the single mutations. For example, TSR7 and TSR8 S to A individually had a relatively modest effect on secretion but mutation of both residues decreased secretion to 11% as compared to 58% for the wild-type ADAMTS13 protein. The decreased presence of the fucosylation site mutants in the medium is not due to increased degradation since inclusion of protease inhibitors in the medium with tetracycline did not increase the amount in the medium (data not shown).
Decreased POFUT2 activity impairs secretion of ADAMTS13
Since the mutation of serines to alanine may impair folding of ADAMTS13 independently of fucose incorporation, fucosylation was blocked in the absence of mutations. Two approaches were used to block fucosylation; first, a CHO cell line, Lec13, that is deficient in GDP-fucose synthesis was utilized (38, 39) . Lec13 cells are defective in the conversion of GDP-mannose to GDP-fucose but are able to make GDP-fucose if exogenous fucose is added to the medium (38, 39) . Since GDP-fucose is the donor for fucosylation, including that mediated by POFUT2, the Lec13 cells have decreased synthesis of fucose containing oligosaccharides. Figure 6 SiRNA experiments were also performed to decrease the activity of POFUT2 in HEK293 cells. HEK293 cells were transfected with POFUT2 with a Flag epitope tag and POFUT2 siRNA or Luciferase siRNA, as a control. The POFUT2 siRNA but not the control Luciferase siRNA decreased expression of the recombinant POFUT2 by more than 90% as seen in Figure 7A (compare lane 1 and 2) demonstrating the efficacy of the siRNA in decreasing expression levels of POFUT2. Subsequently, HEK293 cells were transientlytransfected with ADAMTS13 and with Luciferase siRNA (Luc) or POFUT2 siRNA oligonucleotides, and secretion of ADAMTS13 was examined ( Figure 7B ). The presence of the POFUT2 siRNA reduced secretion of ADAMTS13 consistent with the importance of O-fucosylation in ADAMTS13 secretion (compare lane 4 to lane 2). A low level of secretion is seen with the siRNA experiments. This is to be expected for several reasons; first the half-life of the endogenous POFUT2, which is approximately 10-12 hours (data not shown) prevents complete depletion of POFUT2 within the duration of the transient-transfection experiment. Also, while the efficiency of POFUT2 silencing is very good, it is not 100%; therefore, some POFUT2 continues to be synthesized and may fucosylate multiple ADAMTS13 molecules during the course of the experiment. Inhibition of ADAMTS13 secretion by both mutation of the fucosylation sites and inhibition of POFUT2 activity is strongly Overexpression of POFUT2 promotes TSR1+2 S to A secretionPOFUT1 exhibits a chaperone activity that is distinct from its fucosyltransferase activity since overexpression of fucosyltransferase-inactive POFUT1 promotes the secretion of Notch. To determine if POFUT2 has a chaperone activity in addition to its fucosyltransferase activity, the effect of POFUT2 overexpression on ADAMTS13 secretion was examined. Overexpression of POFUT2 by transient-transfection had no effect on wild-type ADAMTS13 secretion (data not shown). POFUT2 and TSR1+2 S to A were then co-transfected in HEK293 cells. POFUT2 overexpression enabled secretion of TSR1+2 S to A ( Figure 8A , compare lane 2 and 4). Based on the fact that wild-type ADAMTS13 secretion is not enhanced by POFUT2 and that significant amounts of unfucosylated peptides of ADAMTS13 were not seen by mass spectral analysis, the enhancement of secretion of TSR1+2 S to A does not appear to be due to increased fucosylation. Thus, it may be due to a chaperone effect of POFUT2. To determine if POFUT2 activity was needed for secretion of TSR1+2 S to A, POFUT2 E395A/E396A was generated. POFUT2 E395 and E396 are within the conserved DXD motif and mutation of the homologous residues in Drosophila OFUT2 eliminated its fucosyltransferase activity (25) . Overexpression of POFUT2 E395A/E396A did not enhance secretion of TSR1+2 S to A ( Figure  8A , compare lanes 5 and 6 to lanes 3 and 4) but these mutations may have ablated the chaperone activity as well as the fucosyltransferase activity of POFUT2 and prevented the facilitation of secretion. To determine if O-fucose (or Ofucose glycosylation sites) was important for the potential chaperone activity of POFUT2, POFUT2 and TSR1-8 S to A were cotransfected in HEK293 cells. POFUT2 overexpression had no effect on the secretion of TSR1-8 S to A, which lacks all potential fucosylation sites ( Figure 8B , compare lanes 5 and 6 to lanes 3 and 4). This suggests that the presence of O-fucose, or of the O-fucose modification sites, may be important for the chaperone activity of POFUT2.
DISCUSSION
Here we demonstrate that human ADAMTS13 is modified with the disaccharide Glucose-ß1,3-Fucose on most of its TSRs. Preventing O-fucosylation by eliminating multiple O-fucose modification sites, reducing cellular GDP-fucose levels, or reducing POFUT2 using siRNA has a profound effect on secretion of ADAMTS13 from cells. Together these results strongly suggest that Ofucosylation of TSRs plays an important role in processing and secretion of ADAMTS13. Recent results on O-fucosylation of EGF-like repeats within Drosophila Notch suggest that there may be common themes between these two forms of O-fucosylation. Both POFUT1 and POFUT2 are localized to the ER, and both modify properly folded EGF-like repeats and TSRs, respectively (10, (22) (23) (24) . Mutation of Ofucose modification sites causes reduced cellsurface expression of full-length mouse Notch1 (18) , and reduced secretion of Drosophila Notch extracellular doman (22) . Elimination or reduction of OFUT1 in Drosophila prevents cell surface expression of full-length Drosophila Notch or secretion of Drosophila Notch extracellular domain (22) . Drosophila OFUT1 also shows a chaperone-like activity promoting proper folding of Notch, even when its active site is mutated (22) . Here we show that POFUT2 may have a similar chaperone-like activity in addition to its fucosyltransferase activity, in that overexpression of POFUT2 can rescue secretion of TSR1+2 S to A. However, this activity appears to depend on the activity of POFUT2, since an enzymatically inactive mutant POFUT2 does not promote secretion. The presence of O-fucose, or of the O-fucose modification site, appears to be important for the chaperone activity in POFUT2 since POFUT2 overexpression does not enhance secretion of TSR1-8 S to A which lacks O-fucose. It is possible that overexpression of POFUT2 works by increasing the stoichiometry of Ofucosylation on the protein. Further work will define the mechanism of increased secretion with POFUT2 overexpression. Taken together, these results suggest that O-fucosylation of both EGF-like repeats and TSRs plays an important role in processing and secretion of proteins containing these motifs.
There are interesting parallels between the role of N-glycosylation in protein folding and O-fucosylation, both of which occur in the ER (22, 23) . Many glycoproteins require Nlinked glycosylation for proper folding and secretion (41) since the oligosaccharide, which is added co-translationally (42, 43) , can induce a β-turn or prevent premature disulfide bond formation (44, 45) . Chaperones such as calnexin and calreticulin bind to the N-glycans on newly synthesized proteins in the ER and assist in folding (46). Release from the calnexin/calreticulin folding cycle is mediated by removal of a glucose on the N-glycan modifying the folded protein. Recent studies suggest that the resulting high-mannose type Nglycan is recognized by members of the ERGIC53 family of lectins (47) (48) (49) . ERGIC53 appears to function as an export receptor, recognizing the N-glycan on a properly folded protein and removing it from the ER (50) . Ofucosylation may play a similar role. Since proper disulfide-bonding is required for fucosylation of both EGF-like repeats (24) and TSRs (10), folding of EGF-like repeats and TSR occurs before fucosylation. This suggests that POFUT1 and 2 may provide a signal that an individual EGF-like repeat or TSR is folded. This may be especially important for proteins containing multiple, tandem TSRs or EGF-like repeats (such as ADAMTS13 or Notch) to help the folding machinery keep the cysteines from each motif distinct. Consider that ADAMTS13 has 46 cysteines in its TSRs alone, each of which must find its correct partner before the protein is properly folded. Addition of fucose may serve as a signal, telling the cell that the TSRs or EGF-like repeats are folded, before the protein can leave the ER. The fact that the double mutants generally have significantly larger effects than single mutants (Table 3) suggests that the signal comes from multiple sites, not just one. Lectin-like receptors analogous to ERGIC53 may assist in recognizing properly fucosylated proteins for export. Alternatively, fucosylated proteins may be recognized by a chaperone that facilitates higher order folding; lack of recognition by the chaperone would lead to the poor secretion of the fucosylation double mutants of ADAMTS13. A third possibility is that fucosylation prevents deleterious interactions that result in decreased efficiency of secretion. Interestingly, C-terminal truncations of ADAMTS13 that do not contain TSR repeats are well secreted (3, 27, 51) . The presence of TSRs and EGF-like repeats in proteins increases the complexity of folding with three disulfide bonds to correctly form in each repeat. Fucosylation may be needed for this complex folding.
It is unclear why fucosylation of different TSRs has such variable effects on secretion, although variable effects are also seen with mutation of the O-fucosylation sites in Notch EGF-like repeats (18) . One possibility is that a receptor/chaperone (ERGIC53-like) preferentially recognizes fucose (or glucosefucose disaccharide) on some TSRs better than others, or may recognize glycans on multiple TSRs. Alternatively, it may be due to the efficiency with which individual TSRs or EGFlike repeats fold. While the sequences of the individual TSRs in ADAMTS13 share a number of common elements (e.g. all but TSR4 contain six conserved cysteines (TSR4 contains 4 of the 6) and all contain a conserved tryptophan), their sequences and lengths vary significantly (2). The most highly conserved sequence (with the exception of TSR4) is the O-fucose modification site ( Figure 1B) . The fact that serine to alanine mutations within this highly conserved sequence in different TSRs has dramatically different effects on secretion (compare mutation in TSR2 to that in TSR5, 6 or 8, Figure 4 ) argues that the mutation itself is not causing the effect, but that other sequences within the TSR (where there are differences) are contributing. Presumably, the differences in sequence for each TSR will affect the rate and efficiency of folding for that TSR. The lack of secretion of ADAMTS13 in Lec13 cells grown in the absence of fucose (Figure 6 ) or when POFUT2 was reduced by siRNA ( Figure 7 ) supports the idea that loss of the fucose modification is causing the effect and not just the mutation. Further experiments will need to be performed to determine whether the efficiency of folding individual TSRs or EGFlike repeats is affected by O-fucosylation.
The fate of the retained fucosylation site mutants is also unclear. The half-life of cellular wild-type ADAMTS13 is approximately seven hours with most of the protein being secreted (36) . Using pulse-chase experiments, TSR1+2 S to A is detected within the cell even after 24 hours of incubation without secretion (data not shown). It is unclear if intracellular efforts are made to promote secretion of cellular TSR1+2 S to A instead of targeting it for rapid degradation.
TSRs 1,2,3,5,6,7, and 8 of ADAMTS13 all contain the originally described consensus sequence for O-fucosylation of TSRs of CSX(S/T)CG (9) (Figure 1B Table 2 for predicted masses). No other predicted tryptic peptides from human ADAMTS13 correspond to this mass. Further confirmation for the assignment of the peptide comes from peptide fragment ions. Several y-ions from fragmentation of the peptide are shown here. The spectra for the other glycopeptides reported in Table 2 are shown in the Supplemental Data. The small amount of m/z 611.1 in the MS spectra probably corresponds to glycopeptide that lost the saccharide during the ionization process (in-source decay) (52) . O-Fucose is known to be partially lost from glycopeptides during ionization, but O-fucosylated peptides are known to separate from unglycosylated peptides during reverse phase HPLC (52) . Thus, unglycosylated peptide should not appear in the same spectrum as glycopeptide. Additional searches confirm that no unglycosylated peptide can be found in MS spectra at later times in the HPLC run. 
